Neuland Laboratories Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Neuland Laboratories wird ein Gewinn- und Umsatzwachstum von 33.9% bzw. 23.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 33.8% pro Jahr wachsen soll.
Wichtige Informationen
33.9%
Wachstumsrate der Gewinne
33.8%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 17.9% |
| Wachstumsrate der Einnahmen | 23.3% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 07 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09
Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 26,113 | 6,340 | N/A | N/A | 2 |
| 3/31/2026 | 21,750 | 4,976 | 3,569 | 4,369 | 2 |
| 3/31/2025 | 15,901 | 3,229 | 2,773 | 3,512 | 2 |
| 9/30/2024 | 15,283 | 2,797 | 413 | 2,457 | N/A |
| 6/30/2024 | 16,352 | 3,361 | N/A | N/A | N/A |
| 3/31/2024 | 15,586 | 3,001 | 1,175 | 2,612 | N/A |
| 12/31/2023 | 15,809 | 3,171 | N/A | N/A | N/A |
| 9/30/2023 | 14,574 | 2,662 | 2,444 | 3,192 | N/A |
| 6/30/2023 | 13,333 | 2,154 | N/A | N/A | N/A |
| 3/31/2023 | 11,915 | 1,635 | 1,711 | 2,372 | N/A |
| 12/31/2022 | 10,406 | 1,008 | N/A | N/A | N/A |
| 9/30/2022 | 10,078 | 831 | 341 | 1,070 | N/A |
| 6/30/2022 | 9,720 | 651 | N/A | N/A | N/A |
| 3/31/2022 | 9,517 | 638 | -373 | 604 | N/A |
| 12/31/2021 | 9,400 | 593 | N/A | N/A | N/A |
| 9/30/2021 | 9,489 | 731 | 359 | 1,437 | N/A |
| 6/30/2021 | 9,324 | 742 | N/A | N/A | N/A |
| 3/31/2021 | 9,370 | 806 | 840 | 1,894 | N/A |
| 12/31/2020 | 8,852 | 540 | N/A | N/A | N/A |
| 9/30/2020 | 8,436 | 384 | 96 | 887 | N/A |
| 6/30/2020 | 7,884 | 257 | N/A | N/A | N/A |
| 3/31/2020 | 7,640 | 162 | 85 | 573 | N/A |
| 12/31/2019 | 7,443 | 321 | N/A | N/A | N/A |
| 9/30/2019 | 7,120 | 257 | 312 | 899 | N/A |
| 6/30/2019 | 6,945 | 216 | N/A | N/A | N/A |
| 3/31/2019 | 6,675 | 164 | 68 | 699 | N/A |
| 3/31/2018 | 5,284 | 121 | N/A | 113 | N/A |
| 3/31/2017 | 5,789 | 469 | N/A | 387 | N/A |
| 3/31/2016 | 5,100 | 273 | N/A | 448 | N/A |
| 3/31/2015 | 4,692 | 159 | N/A | 132 | N/A |
| 3/31/2014 | 4,657 | 268 | N/A | 488 | N/A |
| 12/31/2013 | 4,619 | 258 | N/A | 545 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NEULANDLABDas prognostizierte Gewinnwachstum (33.9% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: NEULANDLABDie Erträge des Unternehmens (33.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (17.9% pro Jahr).
Hohe Wachstumserträge: NEULANDLABEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: NEULANDLABDie Einnahmen des Unternehmens (23.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.4% pro Jahr).
Hohe Wachstumseinnahmen: NEULANDLABDie Einnahmen des Unternehmens (23.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NEULANDLAB in 3 Jahren voraussichtlich hoch sein wird